<a href="https://laohu8.com/S/DNTH">Dianthus Therapeutics Inc.</a> Files Final Prospectus for $270 Million Public Offering, Expanding Shareholder Opportunities
Dianthus Therapeutics Inc. has filed a final prospectus supplement with the U.S. Securities and Exchange Commission detailing the terms of its latest public offering. The company plans to issue and sell 6,487,879 shares of its common stock at a public offering price of $33.00 per share. Additionally, Dianthus will offer pre-funded warrants to purchase 1,112,121 shares of common stock at a price of $32.999 per warrant, which takes into account a $0.001 per share exercise price. The net proceeds from the offering, expected to be approximately $270 million, will be used after deducting underwriters' discounts, commissions, and estimated offering expenses. The offering is set to close on September 11, 2025, following the full exercise of an option by the underwriters to purchase an additional 1,140,000 shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-200715), on September 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.